2022 Rare Cancer Think Tank

TTAPMRC Invite 29Aug20221200 × 300 px website1 e1661961946516

Presented by TargetCancer Foundation

The Think Tank on Advancing Precision Medicine in Rare Cancers, held on September 21, 2022, was an interactive, one-day meeting that united clinicians, researchers, industry, patient advocates and patients in a unique format to promote collaboration, information sharing, and idea generation. The diverse perspectives of speakers and attendees allowed for a comprehensive discussion of challenges, goals, opportunities and best practices in addressing the needs of patients facing rare cancers.

Screen Shot 2022 12 15 at 12.55.49 PM

View the meeting agenda.

View photos from the meeting.

The Think Tank on Advancing Precision Medicine in Rare Cancers leverages the successful “think tank” model that TargetCancer Foundation has established through over a decade of meetings on other topics, such as gastroesophageal cancers. The Think Tank on Advancing Precision Medicine in Rare Cancers also builds on the progress being made through TargetCancer Foundation’s TCF-001 TRACK study, a nationwide, decentralized, patient-driven clinical trial studying precision medicine in rare cancers. One of the meeting highlights was a mock Molecular Tumor Board meeting featuring members of the TRACK Virtual Molecular Tumor Board.

View video of the mock Molecular Tumor Board. 

We extend our sincere gratitude to our Meeting Chairs and our Keynote speaker, Allen Chankowsky. A very special thank you as well to all of our sponsors for their support in making this meeting a true success.

 Meeting Chairs:
Jennifer Carter, MD, MPH 

Partner, Sandbox Industries; Managing Director, The Blue Venture Fund

John Iafrate, MD, PhD
Deputy Chair of Pathology, Massachusetts General Hospital
Professor of Pathology, Harvard Medical School

Razelle Kurzrock, MD
Professor of Medicine
Founding Director, Michels Rare Cancers Research Laboratories
Froedtert and Medical College of Wisconsin
Principal Investigator, TCF-001 TRACK (Target Rare Cancer Knowledge) Study

2022 RCTT sponsors 09Sep22 updated